Febuxostat (vs. Allopurinol) In Treating the Hyperuricemia of Gout In Diabetic Patients.

被引：0
|
作者：
Becker, Michael A. [1 ]
MacDonald, Patricia A. [2 ]
Hunt, Barbara [2 ]
Jackson, Robert L. [2 ]
机构：
[1] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[2] Takeda Global Res & Dev Ctr Inc, Deerfield, IL USA
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1022
引用
收藏
页码：S399 / S399
页数：1
相关论文
共 50 条
  • [31] Comparison of the efficacy of febuxostat vs. benzbromarone in the treatment of gout: a meta-analysis in Chinese gout patients
    Yan, C. -Q.
    Liang, C.
    Lan, Z. -R.
    Su, C.
    Xiong, S. -Y.
    Yang, Y. -X.
    Chen, J. -M.
    Tang, S. -L.
    Huang, J. -S.
    Zhang, Z. -H
    Luo, M. -J.
    Xiao, Z. -H.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (24) : 11988 - 12003
  • [32] A phase 3 study comparing the safety and efficacy of oral febuxostat and allopurinol in subjects with hyperuricemia and gout.
    Becker, MA
    Schumacher, HR
    Wortmann, RL
    MacDonald, PA
    Palo, W
    Eustace, D
    Joseph-Ridge, N
    ARTHRITIS AND RHEUMATISM, 2004, 50 (12): : 4103 - 4104
  • [33] Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease
    White, William B.
    Gunawardhana, Lhanoo
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [34] Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
    Guan, Xudong
    Zhang, Shengzhao
    Liu, Jiayan
    Wu, Fengbo
    Zhou, Lingyan
    Liu, Ying
    Su, Na
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [35] Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial
    Timilsina, S.
    Brittan, K.
    O'Dell, J. R.
    Brophy, M. C.
    Davis-Karim, A.
    Henrie, A. M.
    Neogi, T.
    Newcomb, J.
    Palevsky, P. M.
    Pillinger, M. H.
    Pittman, D.
    Taylor, T. H.
    Wu, H.
    Mikuls, T. R.
    CONTEMPORARY CLINICAL TRIALS, 2018, 68 : 102 - 108
  • [36] EFECTIVENESS OF FEBUXOSTAT IN PATIENTS WITH GOUT REFRACTORY OR INTOLERANT TO ALLOPURINOL IN CLINICAL PRACTICE
    Munoz Gomez, M. D. M.
    Pavo Blanco, M.
    Blanquez Martinez, D.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S316 - S317
  • [37] Comparison between Allopurinol and Febuxostat in management of gout patients - a prospective study
    Singal, K. K.
    Goyal, S.
    Gupta, P.
    Aggawal, B. K.
    BANGLADESH JOURNAL OF MEDICAL SCIENCE, 2011, 10 (04): : 257 - 259
  • [38] Comparing Clinical Characteristics and Comorbidities of Gout Patients Treated with Allopurinol or Febuxostat
    Becker, Michael A.
    Ye, Xiangyang
    Akhras, Kasem S.
    Tawk, Rima H.
    Unni, Sudhir
    Young, Jason
    Asche, Carl V.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S771 - S772
  • [39] General Safety of Febuxostat and Allopurinol in a Cardiovascular Outcomes Study in Patients with Gout
    Saag, Kenneth
    Becker, Michael A.
    White, William B.
    Whelton, Andrew
    Borer, Jeffrey
    Gorelick, Philip
    Hunt, Barbara
    Castillo, Majin
    Gunawardhana, Lhanoo
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [40] COST-EFFECTIVENESS OF FEBUXOSTAT IN MANAGING HYPERURICEMIA IN GOUT PATIENTS IN SPAIN
    Cuesta, M.
    Perez Alcantara, F.
    Brosa, M.
    VALUE IN HEALTH, 2012, 15 (07) : A513 - A513
12345